AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20307378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 18301879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative heparin infusion
Number of subjects: 20
Study 18301879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16042029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluent aphasics (FA)
Number of subjects: 0
Study 16042029 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's type dementia (DAT)
Number of subjects: 0
Study 16042029 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT patients with lexical‐semantic deficit
Number of subjects: 0
Study 16042029 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT patients with conceptual deficit
Number of subjects: 0
Study 16042029 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study 12079501 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (administered by intravenous infusion every two weeks for 6 months)
Number of subjects: 26
Study 12079501 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 26
Study 12079501 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study 10418756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g once daily (CTX)
Number of subjects: 100
Study 10418756 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (STD)
Number of subjects: 100
Study 7740639 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10-40 mg/day) for three and six weeks
Number of subjects: 66
Study 7740639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 7740639 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10-40 mg/day)
Number of subjects: 66
Study 2040715 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 55
Study 2040715 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 55
Study 2040715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 6799913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose obstructed
Number of subjects: 8
Study 6799913 — intervention group
Group type: COMPARATOR
Intervention: Nose open
Number of subjects: 8
Study 31207693 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB)
Number of subjects: 150
Study 31207693 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 150
Study 31207693 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine general anesthesia)
Number of subjects: 150
Study 28302703 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-element psychosocial intervention
Number of subjects: 444
Study 28302703 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 444
Study 27697302 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-1300 polyepitope DNA vaccine administered via electroporation
Number of subjects: 0
Study 27697302 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 25071414 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured oral information in addition to standard care, covering procedural, sensory, and coping information, and individualized fears and questions; administered in a single episode lasting 10-15 minutes.
Number of subjects: 211
Study 25071414 — intervention group
Group type: COMPARATOR
Intervention: Non-specific episodic conversation of similar length in addition to standard care; administered in a single episode lasting 10-15 minutes.
Number of subjects: 211
Study 21355727 — intervention group
Group type: EXPERIMENTAL
Intervention: Calsulin
Number of subjects: 40
Study 21355727 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 19969180 — intervention group
Group type: EXPERIMENTAL
Intervention: H-reflex gain measurement
Number of subjects: 30
Study 19969180 — intervention group
Group type: EXPERIMENTAL
Intervention: Presynaptic inhibition measurement
Number of subjects: 30
Study 17370153 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (adaptive servoventilation)
Number of subjects: 0
Study 17370153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy
Number of subjects: 0
Study 17370153 — intervention group
Group type: COMPARATOR
Intervention: Optimal drug therapy for heart failure
Number of subjects: 0
Study 15730636 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg, twice daily for 5 days
Number of subjects: 1176
Study 15730636 — intervention group
Group type: COMPARATOR
Intervention: Control group (symptom relief medicine)
Number of subjects: 1176
Study 11777221 — intervention group
Group type: EXPERIMENTAL
Intervention: Clariscan 0.75 mg Fe/kg body weight
Number of subjects: 6
Study 11777221 — intervention group
Group type: EXPERIMENTAL
Intervention: Clariscan 2 mg Fe/kg body weight
Number of subjects: 6
Study 11777221 — intervention group
Group type: EXPERIMENTAL
Intervention: Clariscan 5 mg Fe/kg body weight
Number of subjects: 6
Study 9133758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (n = 56)
Number of subjects: 168
Study 9133758 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (n = 52)
Number of subjects: 168
Study 9133758 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 60)
Number of subjects: 168
Study 8201224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 750 mg/day
Number of subjects: 27
Study 8201224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3296605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 25 mg
Number of subjects: 602
Study 3296605 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 602
Study 3296605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 29868853 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad combined with febuxostat (2.5-10 mg with febuxostat 10, 20, 40 mg)
Number of subjects: 72
Study 29868853 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad alone (2.5-15 mg)
Number of subjects: 72
Study 29868853 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat alone (10, 20, 40 mg)
Number of subjects: 72
Study 29868853 — intervention group
Group type: COMPARATOR
Intervention: Benzbromarone alone (50 mg)
Number of subjects: 72
Study 26882370 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein (HP) formula
Number of subjects: 141
Study 26882370 — intervention group
Group type: COMPARATOR
Intervention: Lower protein (LP) formula
Number of subjects: 141
Study 26882370 — intervention group
Group type: COMPARATOR
Intervention: Breastfed (BF) infants
Number of subjects: 141
Study 25338798 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal-pulp combined therapy
Number of subjects: 52
Study 25338798 — intervention group
Group type: COMPARATOR
Intervention: Periodontal therapy (Control)
Number of subjects: 52
Study 23744101 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation without intraoperative testing
Number of subjects: 609
Study 23744101 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock path reversal
Number of subjects: 609
Study 19468759 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge-planning program, discharge teaching, home visits, and telephone consultation
Number of subjects: 49
Study 19468759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study 18460487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sous vide cooked salmon fish
Number of subjects: 21
Study 18460487 — intervention group
Group type: COMPARATOR
Intervention: Bean meal (rich in phytate)
Number of subjects: 21
Study 18460487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish and bean meal
Number of subjects: 21
Study 17145226 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 mug/kg/min for 24 hours)
Number of subjects: 45
Study 17145226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12691128 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative gated myocardial SPECT (QGS) with 99mTc-tetrofosmin
Number of subjects: 179
Study 10972599 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (50 microg/kg)
Number of subjects: 20
Study 10972599 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (0.03 microg/kg/min)
Number of subjects: 20
Study 8873202 — intervention group
Group type: EXPERIMENTAL
Intervention: Two modes of presentation (not specified)
Number of subjects: 0
Study 8873202 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different presentation rates (not specified)
Number of subjects: 0
Study 8873202 — intervention group
Group type: EXPERIMENTAL
Intervention: Two significantly different levels of adult intelligence
Number of subjects: 0
Study 8873202 — intervention group
Group type: COMPARATOR
Intervention: Compressed speech technology (not specified)
Number of subjects: 0
Study 1305670 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaditen (ketotifen)
Number of subjects: 0
Study 1305670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3893329 — intervention group
Group type: EXPERIMENTAL
Intervention: Current formula milk
Number of subjects: 10
Study 3893329 — intervention group
Group type: COMPARATOR
Intervention: Earlier type with higher protein and mineral content
Number of subjects: 10
Study 31092727 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional B cells in healthy donors
Number of subjects: 0
Study 31092727 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature B cells in healthy donors
Number of subjects: 0
Study 31092727 — intervention group
Group type: COMPARATOR
Intervention: Transitional to mature B cells in SLE patients
Number of subjects: 0
Study 31092727 — intervention group
Group type: EXPERIMENTAL
Intervention: Mature B cells from healthy donors
Number of subjects: 0
Study 29400576 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute
Number of subjects: 220
Study 29400576 — intervention group
Group type: COMPARATOR
Intervention: Regular salt
Number of subjects: 220
Study 28078860 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural block
Number of subjects: 24
Study 28078860 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone
Number of subjects: 24
Study 25076084 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling
Number of subjects: 37
Study 25076084 — intervention group
Group type: COMPARATOR
Intervention: Liquid nitrogen cryotherapy
Number of subjects: 37
Study 21692869 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) treatment
Number of subjects: 28
Study 21692869 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 28
Study 20593247 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammatory response syndrome (SIRS)
Number of subjects: 413
Study 20593247 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS burden (number of SIRS variables per day over the first 4 days)
Number of subjects: 413
Study 20593247 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping vs. endovascular coiling
Number of subjects: 413
Study 20593247 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRS
Number of subjects: 413
Study 17437502 — intervention group
Group type: EXPERIMENTAL
Intervention: Home fecal occult blood test (FOBT)
Number of subjects: 1808
Study 17437502 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening endoscopy
Number of subjects: 1808
Study 17437502 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CRC screening
Number of subjects: 1808
Study 17437502 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's recommendation for screening
Number of subjects: 1808
Study 15389228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 500 mg immediately before the procedure
Number of subjects: 487
Study 15389228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 11437760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 90 mg
Number of subjects: 60
Study 11437760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg
Number of subjects: 60
Study 11437760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9520235 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 21
Study 7925519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine CC (40 mg oral dose)
Number of subjects: 24
Study 7925519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2768942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node dissection
Number of subjects: 183
Study 2768942 — intervention group
Group type: COMPARATOR
Intervention: No lymph node dissection
Number of subjects: 183
Study 63748 — intervention group
Group type: EXPERIMENTAL
Intervention: sulphafurazole (sulfisoxazole), 500 mg orally q.i.d. for 10 days
Number of subjects: 91
Study 63748 — intervention group
Group type: EXPERIMENTAL
Intervention: aminocyclitols (streptomycin or spectinomycin), 2 g intramuscularly for 1 to 3 doses at 12 h intervals
Number of subjects: 91
Study 63748 — intervention group
Group type: COMPARATOR
Intervention: C+U+ N.G.U.
Number of subjects: 91
Study 30661559 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic cognitive behavioral therapy (CBT)
Number of subjects: 1092
Study 28098099 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) levels
Number of subjects: 84
Study 28098099 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10 (IL-10) levels
Number of subjects: 84
Study 28098099 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic acidosis and serum bicarbonate levels
Number of subjects: 84
Study 25864152 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives to eat
Number of subjects: 353
Study 25864152 — intervention group
Group type: COMPARATOR
Intervention: Monetary incentives not to eat
Number of subjects: 353
Study 23568940 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in consent (n = 564)
Number of subjects: 1129
Study 23568940 — intervention group
Group type: COMPARATOR
Intervention: Opt-out consent (n = 565)
Number of subjects: 1129
Study 23568940 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall support for data linkage
Number of subjects: 1129
Study 23568940 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in privacy protections
Number of subjects: 1129
Study 23568940 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental concerns about serious reactions
Number of subjects: 1129
Study 23568940 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for consent type
Number of subjects: 1129
Study 23568940 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization status of babies
Number of subjects: 1129
Study 23568940 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in vaccine safety
Number of subjects: 1129
Study 21915570 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulsed electromagnetic field device
Number of subjects: 259
Study 21915570 — intervention group
Group type: COMPARATOR
Intervention: Inactive pulsed electromagnetic field device (placebo)
Number of subjects: 259
Study 21915570 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulsed electromagnetic field device (compliant group)
Number of subjects: 259
Study 21915570 — intervention group
Group type: COMPARATOR
Intervention: Combined placebo and active, noncompliant group
Number of subjects: 259
Study 21915570 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and placebo groups (overall)
Number of subjects: 259
Study 19828711 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified milk (1.5 mg iron/100 g prepared milk)
Number of subjects: 225
Study 19828711 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat (approximately 2.6 mg iron from red meat dishes daily)
Number of subjects: 225
Study 19828711 — intervention group
Group type: COMPARATOR
Intervention: Control (nonfortified milk with 0.01 mg iron/100 g prepared milk)
Number of subjects: 225
Study 16760795 — intervention group
Group type: EXPERIMENTAL
Intervention: ART + three 5-day cycles of IL-2 at 4.5 million U, Sc, BID every 8 weeks (n = 23)
Number of subjects: 47
Study 16760795 — intervention group
Group type: COMPARATOR
Intervention: ART alone (n = 24)
Number of subjects: 47
Study 16760795 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (IL-2 and ART alone)
Number of subjects: 47
Study 16760795 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 before TI
Number of subjects: 47
Study 16228176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support
Number of subjects: 17
Study 16228176 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Number of subjects: 17
Study 16228176 — intervention group
Group type: EXPERIMENTAL
Intervention: T-piece
Number of subjects: 17
Study 16228176 — intervention group
Group type: EXPERIMENTAL
Intervention: T-piece with heliox
Number of subjects: 17
Study 16228176 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation
Number of subjects: 17
Study 16228176 — intervention group
Group type: COMPARATOR
Intervention: T-piece ventilation
Number of subjects: 17
Study 12386642 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIS (400 microg/kg)
Number of subjects: 12
Study 12386642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10423226 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand N (RMP + INH tablet)
Number of subjects: 12
Study 10423226 — intervention group
Group type: COMPARATOR
Intervention: Brand R (reference brand R, RMP + INH tablet)
Number of subjects: 12
Study 10423226 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand L (RMP + INH capsule)
Number of subjects: 12
Study 7576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP), > or = 10 prophylactic aerosols
Number of subjects: 49
Study 7576325 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized pentamidine (AP), first exposure
Number of subjects: 49
Study 7576325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerosolized pentamidine)
Number of subjects: 49
Study 7576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized pentamidine (AP), long-term exposure
Number of subjects: 49
Study 2149088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 200 micrograms
Number of subjects: 15
Study 2149088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 800 micrograms
Number of subjects: 15
Study 2149088 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 40 micrograms
Number of subjects: 15
Study 2149088 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 160 micrograms
Number of subjects: 15
Study 92091 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol (Megace, 120 mg./day)
Number of subjects: 61
Study 92091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 92091 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol
Number of subjects: 61
Study 31000658 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized measurements for probing second-order RÃ©nyi entropy
Number of subjects: 10
Study 31000658 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of disorder
Number of subjects: 10
Study 31000658 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of disorder
Number of subjects: 10
Study 28470117 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized yoga intervention (8-week program)
Number of subjects: 0
Study 28470117 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 26248248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS) protocol
Number of subjects: 116
Study 26248248 — intervention group
Group type: COMPARATOR
Intervention: Non-FTS postoperative care
Number of subjects: 116
Study 23471856 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous skin elevation
Number of subjects: 30
Study 23471856 — intervention group
Group type: COMPARATOR
Intervention: Sub-SMAS skin elevation
Number of subjects: 30
Study 22134057 — intervention group
Group type: EXPERIMENTAL
Intervention: A-Zn toothpaste
Number of subjects: 28
Study 22134057 — intervention group
Group type: EXPERIMENTAL
Intervention: B-experimental toothpaste (Zn citrate + PVM/MA copolymer)
Number of subjects: 28
Study 22134057 — intervention group
Group type: COMPARATOR
Intervention: C-control toothpaste without Zn
Number of subjects: 28
Study 19124628 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 (1000 mcg sublingual) for 6 months
Number of subjects: 58
Study 17605487 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma light curing
Number of subjects: 25
Study 17605487 — intervention group
Group type: COMPARATOR
Intervention: LED light curing
Number of subjects: 25
Study 15151491 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised supervised physiotherapy treatment
Number of subjects: 58
Study 15151491 — intervention group
Group type: COMPARATOR
Intervention: Standardised unsupervised home exercise regime
Number of subjects: 58
Study 15151491 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised physiotherapy treatment
Number of subjects: 58
Study 15151491 — intervention group
Group type: COMPARATOR
Intervention: Standardised home exercise regime
Number of subjects: 58
Study 11481625 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (0.5, 1.0, or 1.5 microg/kg, once-weekly)
Number of subjects: 1219
Study 11481625 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (1.5 microg/kg)
Number of subjects: 1219
Study 11481625 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (all doses)
Number of subjects: 1219
Study 11481625 — intervention group
Group type: COMPARATOR
Intervention: interferon alfa-2b (3 MIU, three-times-weekly)
Number of subjects: 1219
Study 9494998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical installation of 30 mg capsaicin in 100 ml of 30% alcohol
Number of subjects: 12
Study 9494998 — intervention group
Group type: COMPARATOR
Intervention: 100 ml 30% alcohol alone (control group)
Number of subjects: 12
Study 8041178 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (alpha‐tocopherol)
Number of subjects: 28